Momenta rises on upgrade ahead of Lovenox ruling Nov 20, 2009
Oppenheimer analyst Bret Holley agreed that ruling will come soon, and he thinks the agency will approve Momenta's version, along with a competing generic made by Teva Pharmaceutical Industries Ltd.. Holley raised his rating on the stock to "Outperform" from "Perform," and set a price target of $15 per share. (Yahoo News -- Pharmaceutical Industry News)
Cephalon, Barr settle Fentora dispute Nov 13, 2009
Barr is now part of Israel-based Teva Pharmaceutical Industries. The deal doesn't affect the status of the separate Fentora patent lawsuits with Watson Pharmaceuticals Inc. and its units. (Yahoo News -- Pharmaceutical Industry News)
Merckle's Ratiopharm Said to Get Offers From Goldman, Advent, TPG, Sanofi Nov 12, 2009
Generic drugmakers Teva Pharmaceutical Industries of Israel, U.S.-based Mylan Inc. and Actavis Group of Iceland, as well as Chinese drugmaker Sinopharm Group Co. Ltd., and private equity firm Permira are also among the bidders, said one of the people. A sale of the Ulm, Germany-based drugmaker would help pay debts amassed by , who committed suicide in January after making wrong-way bets on the stock market. (Bloomberg -- Germany)
Teva gets FDA approval for generic Prevacid Nov 11, 2009
NEW YORK Teva Pharmaceutical Industries Ltd. said Tuesday the Food and Drug Administration approved its generic version of the heartburn drug Prevacid. Teva will sell 15-milligram and 30-milligram delayed-release capsule versions of the drug. (Yahoo News -- Pharmaceutical Industry News)
Generic Drugs' New Frontier Nov 7, 2009
Teva Pharmaceutical Adr. Novartis Ag Adr. (Investors Business Daily)
Buffett Bets 'All In' On U.S., Coal With $44 Bil Railroad Buy Nov 4, 2009
Teva Pharmaceutical (TEVA) was boosted by sales of its multiple sclerosis drug Copaxone and strength in its respiratory business. It sees '09 EPS of. (Investors Business Daily)
Mepha Pharma will receive first round bids on 23 October Oct 21, 2009
A second source noted that the interested suitors so far include Teva Pharmaceutical, STADA Arzneimittel. Pfizer might also be interested. (FT.com -- Markets)
Hospira gets global rights to generic blood drug Oct 1, 2009
(Reuters) Hospital products and generic drugmaker said on Wednesday it acquired worldwide rights to a generic version of the white blood-cell boosting drug filgrastim from Teva Pharmaceutical Industries Ltd.. As part of the deal, for which financial terms were not released, Hospira also gains process development capabilities and a manufacturing plant in Croatia. (Crain's Chicago Business)
Drugmaker Focuses On Niches The Bigger Companies Ignore Sep 30, 2009
Teva Pharmaceutical Adr ... Competing makers include Teva Pharmaceutical (), Alcon (), Apotex, Bausch & Lomb and the Sandoz unit of Novartis (). (Investors Business Daily)
Merck Sued Over Patent on Allergy Drug Singulair Aug 15, 2009
Generic drugmakers Roxane Pharmaceuticals, Teva Pharmaceutical Industries Ltd. and Mylan Inc. have all received Food and Drug Administration approval for versions of Singulair. Merck sued those companies for patent infringement, and none of the generics have reached the market. (ABC News -- Wire)
Indexes Retreat, But Close Off Lows Jul 31, 2009
Gains in Intuitive Surgical (ISRG), Teva Pharmaceutical Industries (TEVA), Celgene (CELG). 07/28/2009 05:43 PM ET. (Investors Business Daily)
Earnings roundup: Viacom, Teva Pharmaceutical Jul 29, 2009
NEW YORK (AP) Teva Pharmaceutical Industries Ltd., the world's largest generic drugmaker by revenue, said its profit slipped 2 percent in the second quarter due to expenses related to its purchase of Barr Pharmaceuticals. BELLEVUE, Wash. (Yahoo News -- Pharmaceutical Industry News)
Nasdaq Edges Higher While Others Slip Jul 29, 2009
Gains in Intuitive Surgical (), Teva Pharmaceutical Industries (), Celgene (), Amgen () and Check Point Software () boosted the index. The narrower Nasdaq 100 also rose 0. (Investors Business Daily)
What Are You Waiting For? Jul 20, 2009
Finally, health care and pharma could have been good plays with both UnitedHealth Group (NYSE: UNH) and Teva Pharmaceutical (Nasdaq: TEVA) growing at healthy rates on average. That's the way to riches -- starting with just a few hundred dollars and combining it with time. (MSNBC -- Business)
FDA OKs Single-Dose Plan B Emergency Contraceptive Jul 15, 2009
The new Plan B One-Step will be available at pharmacies in August, Teva Pharmaceutical Industries Ltd. said Monday ... SOURCE: Teva Pharmaceuticals, Inc., news release, July 13, 2009. (MEDLINEplus)
Lupin shares drop by 5 pc on BSE Jul 9, 2009
The decision concerns generic companies including Krka d.D., Lupin, Matrix Laboratories (a subsidiary of Mylan Inc), Niche Generics and Teva UK / Teva Pharmaceutical Industries, as regards number of individual, possibly restrictive, agreements between each of them and France-based Les Laboratories Servier, the European Commission said in a statement. Read business stories in. (India Times)
EU probes generic drug makers over medicine entry delay Jul 9, 2009
Teva Pharmaceutical Industries, France-based Servier and other generic drug makers are facing EU antitrust investigations of agreements that may have delayed market entry of a cardiovascular medicine. The investigations, which include Krka Group, India's Lupin, Mylan's Matrix Laboratories unit and the Niche Generics unit of Unichem Laboratories, concern deals that may have hindered the market entry of a generic version of Servier's perindopril, a hypertension medication. (Business Report, South Africa)
EU Opens Antitrust Case Against Drug Makers Jul 9, 2009
B), (KRKG.LJ), (LSV.YY), Mylan Laboratories Inc. (MYL), Teva Pharmaceutical Industries Ltd. (TEVA), (TEVA.TV), (IL000629), (INE326A0), (INE351A0), (INE604D0), (SI003110), (US628530)) at SmartMoney ... The commission, the European Union's regulatory arm, said Teva Pharmaceutical Industries Ltd. (TEVA), Krka d.d. (KRKG.LJ), Lupin Ltd. (500257. (SmartMoney)
Teva, Antares get FDA OK for hormone in new device Jun 30, 2009
NEW YORK Teva Pharmaceutical Industries Ltd. and Antares Pharma Inc. said Monday the companies received Food and Drug Administration approval for use of the human growth hormone Tev-Tropin in a needle-free injection system. The drug is already approved as an injection. (Yahoo News -- Pharmaceutical Industry News)
Abbott Spinoff Makes Disparate Parts Work Together Jun 27, 2009
Teva Pharmaceutical Adr ... 1 billion and had to fend off Israel's Teva Pharmaceutical Industries () and Swiss Novartis (). (Investors Business Daily)
Watson to go global with $1.75 billion Arrow buy Jun 20, 2009
Watson's main rivals in the U.S. market -- Teva Pharmaceutical Industries (TEVA.TA), Mylan Inc (MYL.O) and the Sandoz unit of Novartis (NOVN.VX) -- have been more substantial global players, due to their own acquisitions ... Morningstar analyst Brian Laegler said: "After adjusting for generic Lipitor, which is huge, they paid a fair price for it. "I'm neutral on the deal, but it's a step in the right direction," Laegler said. Watson will pay 1.05 billion in cash and issue about 16.9 million... (Yahoo News -- Pharmaceutical Industry News)
Watson Pharma to Buy Arrow Group for $1.75B Jun 18, 2009
The world's largest generic drugmaker, Teva Pharmaceutical Industries Ltd., reported $11. 09 billion in revenue in 2008. (ABC News -- Wire)
5 Spanish centers join a study for a new leukemia and lymphoma treatment technique Jun 4, 2009
StemEx is being developed by a Joint Venture of Gamida Cell and Teva Pharmaceutical Industries (NASDAQ: TEVA) ... Gamida Cell's current shareholders include: Elbit Imaging, Biomedical Investment, Israel Healthcare Venture, Teva Pharmaceutical Industries, Amgen, Denali Ventures and Auriga Ventures. (EurekAlert! -- Business News)
The Year of Affordable Healthcare Brings Together San Francisco Community Groups to Tackle Healthcare Crisis May 29, 2009
SAN FRANCISCO, May 28 /PRNewswire-USNewswire/ -- Teva Pharmaceuticals USA, the leading generic pharmaceutical company, today held the first in a series of community roundtables as part of their Year of Affordable Healthcare campaign () ... Teva USA is a wholly-owned subsidiary of Teva Pharmaceutical Industries Ltd., one of the largest generic pharmaceutical companies in the world and among the top 20 pharmaceutical companies ... SOURCE Teva Pharmaceuticals USA. (PR Newswire)
Gilead files 2nd patent suit against Teva May 16, 2009
filed a second lawsuit in U.S. District Court in New York against and Teva Pharmaceutical Industries Ltd. alleging patent infringement ... The lawsuit is based on an Abbreviated New Drug Application filed by Teva Pharmaceuticals USA Inc., which seeks approval to manufacture and market a generic version of Atripla before the expiration of both emtricitabine patents ... Gilead now has two lawsuits pending against Israel-based Teva Pharmaceuticals. (San Jose Business Journal, CA)
FDA expands access to Plan B for 17-year-olds Apr 28, 2009
The drug is made by a subsidiary of Teva Pharmaceutical Industries, an Israeli company. It does not prevent sexually transmitted infections, such as HIV/AIDS.. (MSNBC -- Health)
Generic Drugs' Biggest Maker Buys Up Rivals Apr 18, 2009
Teva Pharmaceutical Adr ... Teva Pharmaceutical (), the world's biggest maker of generic drugs, got bigger a few months ago with the purchase of Barr Pharmaceuticals, the No. 4 generic drugmaker, for $7 ... Just as Teva Pharmaceutical is busy digesting its latest buy, management is working up an appetite for more. (Investors Business Daily)
Consumers Express Optimism Economy Has Begun To Turn Apr 9, 2009
Just as Teva Pharmaceutical is busy digesting its latest buy, management is working up an appetite for more. Teva (TEVA), the world's largest manufacturer of generic drugs, got a nice boost from its December purchase of Barr Pharmaceuticals. (Investors Business Daily)
World's Biggest Generic Drugmaker Adds Muscle With Acquisition Apr 9, 2009
Teva Pharmaceutical Adr ... Just as Teva Pharmaceutical () is busy digesting its latest buy, management is working up an appetite for more ... Teva Pharmaceuticals (TEVA) finds itself in a tightly formed base. (Investors Business Daily)
Smokers' Lung Treatment May Fail to Fire Up Bidders as Nycomed Seeks Buyer Apr 9, 2009
Novartis AG, which sells the Xolair asthma drug, and Teva Pharmaceutical Industries Ltd, the worlds largest generic-drug maker, may also be interested, another person said. London-based may see potential in Daxas, according to , a fund manager at AXA Framlington in London. (Bloomberg -- Europe)
Generic Biotech Effort Picks up Steam in Congress Mar 27, 2009
a longtime ally of generic drugmakers like Teva Pharmaceutical Industries. Similar to Waxman's bill, Schumer would have the FDA determine whether a company must test its generic biotech drug on patients before launching it. (ABC News -- Wire)
Judge orders FDA to let 17-year-olds use morning-after pill Mar 24, 2009
Korman ordered the FDA to permit Barr Pharmaceuticals, which was bought by Israel-based Teva Pharmaceutical Industries Ltd. late last year, to make Plan B available to 17-year-olds without a prescription under the same conditions as Plan B is now available to women over the age of 18. He said his order must be complied with within 30 days. (KHOU.com, TX)
Judge Overtruns FDA Decision on Morning After Pill Mar 24, 2009
Barr is now owned by Teva Pharmaceutical Industries, a global company headquartered in Israel. (Copyright 2009 by The Associated Press. (W-USA News, DC)
Judge: Lift age barriers on morning-after pill Mar 24, 2009
Plan B is produced by Barr Pharmaceuticals, which was bought by Israel-based Teva Pharmaceutical Industries late last year. In addition to the the Center for Reproductive Rights, the lawsuit was brought by others advocating for wider distribution and access to emergency contraceptives, including parents and their minor children seeking access. (USA Today)
Taxing the Alphabet, and Other Top Stories Mar 21, 2009
In other CourtTV news, OSI Pharmaceuticals demands that Teva Pharmaceutical Industries (Nasdaq: TEVA) and Mylan (NYSE: MYL) be banned from selling their generic version of cancer pill Tarceva, alleging it infringes on three OSI patents. If unsuccessful, OSI will face direct competition for its $457 million in 2008 U.S.-only Tarceva sales -- and that could affect its goal of reaching the $2 billion mark in worldwide sales it envisions hitting in 2011. (MSNBC -- Business)
Medicis and Teva Announce Settlement Agreement Mar 19, 2009
and JERUSALEM, March 18, 2009 (GLOBE NEWSWIRE) -- Medicis (NYSE: - ) and Teva Pharmaceutical Industries Ltd. (NasdaqGS: - ) (Teva) today announced they have agreed to terminate all legal disputes between them relating to SOLODYN(R) (minocycline HCl, USP) Extended Release Tablets ... Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 20 pharmaceutical companies in the world and is the world's leading generic pharmaceutical company. (Primezone Releases)
> Rules still unclear on regulating bioengineered generic drugs Mar 18, 2009
Teva Pharmaceutical Industries Ltd. in February 2008 was the first biosimilar to win European Union approval. Biogenerics could ring up more than $34 billion in sales from 2013 through 2017, according to Medco Health Solutions Inc., which manages pharmacy benefits for employers and health plans. (San Jose Business Journal, CA)
Statement by Teva Pharmaceuticals on Eshoo-Barton Bill Mar 18, 2009
March 17 /PRNewswire-USNewswire/ -- Teva Pharmaceuticals USA, the leading generic pharmaceutical company, today released the following statement by Debra Barrett, Senior Vice President of Government Affairs on the introduction of a biogenerics bill by Representatives Anna Eshoo and Joe Barton ... " About Teva Teva USA is a wholly-owned subsidiary of Teva Pharmaceutical Industries Ltd., one of the largest generic pharmaceutical companies in the world and among the top 20 pharmaceutical companies.... (PR Newswire)
XplosiveStocks.com: SGP, TEVA, SBUX, MO, Q, NLY Hot Stock Alerts! Mar 14, 2009
Today's hot alerts include: Schering-Plough Corp. (NYSE:), Teva Pharmaceutical Industries Ltd. (NASDAQ:), Starbucks Corp. (NASDAQ: ), Altria Group, Inc. (NYSE:), Qwest Communications International, Inc. (NYSE:), and Annaly Capital Management, Inc. (NYSE:). XplosiveStocks. (PR Newswire)
Israeli-based generic drug maker Teva considering Willow Grove military base Mar 7, 2009
Generic drug company Teva Pharmaceuticals USA is seeking a major expansion of its local operations and is figuring out where to undertake that growth near its current U.S. headquarters in North Wales or further away in South Jersey or Delaware ... COMPANY: Teva Pharmaceutical Industries Ltd.LOCATION: IsraelUSA HEADQUARTERS: North Wales PRESIDENT AND CEO: Shlomo YanaiTYPE OF COMPANY: Generic pharmaceutical manufacturer2008 NET INCOME: $635 million2008 REVENUE: $11. (Philadelphia Business Journal, PA)
I.D. Systems Reports Financial Results for Fourth Quarter and Fiscal Year 2008-Year Over Year Revenues Increase 58% Mar 6, 2009
-- The U.S. subsidiary of Teva Pharmaceutical Industries Ltd., a top-20 global pharmaceutical company and the world's leading generic pharmaceutical company with fiscal 2008 revenues of $11. 1 billion. (Primezone Releases)
Shire full-year revenue meets forecasts Feb 19, 2009
Shire is pinning hopes on Vyvanse and its human genetic therapy products for rare diseases to drive sales when Israel's Teva Pharmaceutical Industries gets the rights to start selling a generic version of Adderall XR in April. Shire trades on about 14 times forecast 2009 earnings, compared with 10 times for British peer GlaxoSmithKline and about 7 times for AstraZeneca Plc. (International Herald Tribune -- Travel)
Teva makes Q4 net loss on Barr acquisition costs Feb 17, 2009
TEL AVIV, Feb 17 (Reuters) - Teva Pharmaceutical Industries Ltd (TEVA.O) (TEVA.TA), the world's largest generic drugmaker, fell to a net loss in the fourth quarter due to costs associated with its acquisition of rival Barr Pharmaceuticals. Teva made a fourth-quarter net loss of $688 million, or 88 cents per share, compared with a net profit of $570 million, or 69 cents a diluted share, a year earlier, the company said on Tuesday. (Reuters)
MS Drug Prize Worth $1.3 Billion Spurs Race Between Merck KGaA, Novartis Feb 14, 2009
Merck, of Darmstadt, Germany, and Novartis, of Basel, Switzerland, are running ahead of Teva Pharmaceutical Industries Ltd., Biogen Idec Inc. and Sanofi-Aventis SA in the chase for an oral treatment. The results may shake up the $6 billion multiple sclerosis market. (Bloomberg)
